MULTIPLE MYELOMA IN ELDERLY AFRO-CARIBBEAN PATIENTS TREATED WITH MEPHALAN PREDNISONE AND THALIDOMIDE IN MARTINIQUE;A RETROSPECTIVE STUDY
(Abstract release date: 05/21/15)
EHA Library. Lok A. 06/12/15; 102899; PB1890
Disclosure(s): CHU NantesHematology
Anne Lok
Contributions
Contributions
Abstract
Abstract: PB1890
Type: Publication Only
Background
In African-Americans (AA), the incidence of multiple myeloma (MM) is twice as high as in Caucasians. Only few studies have focused on overall survival. A recent population-based study comparing white and AA subjects showed a better survival in AA patients over a entire study period ranging from 1973 to 2005. However, significant survival improvement after the current era of intensive treatment or new therapies was only seen among whites, with smaller, non-significant change seen among blacks .This study hypothesized that the disparities in improvement in outcome observed could be related to a lower response to new therapies in AA patients. In Martinique, a French overseas department, the vast majority of the population is of Afro-Caribbean origin .
Aims
Our aim was to assess the characteristics, progression-free (PFS) and overall survival (OS) of this ethnicity subgroup.
Methods
We conducted a retrospective study on transplant-ineligible patient, newly diagnosed with MM who were treated in the Hematology Department of Fort de France in Martinique between 2007 and 2012.
Results
During this period, the Martinique Association for Epidemiological Research on Cancer revealed an incidence of 8/100,000 inhabitants per year. Fifty four patients were not eligible for autologous stem cell transplantation and had been treated with melphalan, prednisone and thalidomide as part of frontline therapy.The patients had a median age of 80 years, with ISS stage III documented in 48%. The overall response rate was 76%. With a median follow up of 35 months, PFS and OS were 28.9 months and 48.6 months.
Summary
Compared to metropolitan France, our results show a higher incidence and a similar outcome in this population, despite an advanced age and disease status at diagnosis. No data have been published focusing only on the outcome of AA or African-Caribbean elderly patients treated with combination therapies that include novel agents. Our study highlights findings which had so far not been described and do not support the hypothesis that AA patients had a lower response to new therapies.
Keyword(s): Elderly, Ethnicity, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
In African-Americans (AA), the incidence of multiple myeloma (MM) is twice as high as in Caucasians. Only few studies have focused on overall survival. A recent population-based study comparing white and AA subjects showed a better survival in AA patients over a entire study period ranging from 1973 to 2005. However, significant survival improvement after the current era of intensive treatment or new therapies was only seen among whites, with smaller, non-significant change seen among blacks .This study hypothesized that the disparities in improvement in outcome observed could be related to a lower response to new therapies in AA patients. In Martinique, a French overseas department, the vast majority of the population is of Afro-Caribbean origin .
Aims
Our aim was to assess the characteristics, progression-free (PFS) and overall survival (OS) of this ethnicity subgroup.
Methods
We conducted a retrospective study on transplant-ineligible patient, newly diagnosed with MM who were treated in the Hematology Department of Fort de France in Martinique between 2007 and 2012.
Results
During this period, the Martinique Association for Epidemiological Research on Cancer revealed an incidence of 8/100,000 inhabitants per year. Fifty four patients were not eligible for autologous stem cell transplantation and had been treated with melphalan, prednisone and thalidomide as part of frontline therapy.The patients had a median age of 80 years, with ISS stage III documented in 48%. The overall response rate was 76%. With a median follow up of 35 months, PFS and OS were 28.9 months and 48.6 months.
Summary
Compared to metropolitan France, our results show a higher incidence and a similar outcome in this population, despite an advanced age and disease status at diagnosis. No data have been published focusing only on the outcome of AA or African-Caribbean elderly patients treated with combination therapies that include novel agents. Our study highlights findings which had so far not been described and do not support the hypothesis that AA patients had a lower response to new therapies.
Keyword(s): Elderly, Ethnicity, Multiple myeloma
Session topic: Publication Only
Abstract: PB1890
Type: Publication Only
Background
In African-Americans (AA), the incidence of multiple myeloma (MM) is twice as high as in Caucasians. Only few studies have focused on overall survival. A recent population-based study comparing white and AA subjects showed a better survival in AA patients over a entire study period ranging from 1973 to 2005. However, significant survival improvement after the current era of intensive treatment or new therapies was only seen among whites, with smaller, non-significant change seen among blacks .This study hypothesized that the disparities in improvement in outcome observed could be related to a lower response to new therapies in AA patients. In Martinique, a French overseas department, the vast majority of the population is of Afro-Caribbean origin .
Aims
Our aim was to assess the characteristics, progression-free (PFS) and overall survival (OS) of this ethnicity subgroup.
Methods
We conducted a retrospective study on transplant-ineligible patient, newly diagnosed with MM who were treated in the Hematology Department of Fort de France in Martinique between 2007 and 2012.
Results
During this period, the Martinique Association for Epidemiological Research on Cancer revealed an incidence of 8/100,000 inhabitants per year. Fifty four patients were not eligible for autologous stem cell transplantation and had been treated with melphalan, prednisone and thalidomide as part of frontline therapy.The patients had a median age of 80 years, with ISS stage III documented in 48%. The overall response rate was 76%. With a median follow up of 35 months, PFS and OS were 28.9 months and 48.6 months.
Summary
Compared to metropolitan France, our results show a higher incidence and a similar outcome in this population, despite an advanced age and disease status at diagnosis. No data have been published focusing only on the outcome of AA or African-Caribbean elderly patients treated with combination therapies that include novel agents. Our study highlights findings which had so far not been described and do not support the hypothesis that AA patients had a lower response to new therapies.
Keyword(s): Elderly, Ethnicity, Multiple myeloma
Session topic: Publication Only
Type: Publication Only
Background
In African-Americans (AA), the incidence of multiple myeloma (MM) is twice as high as in Caucasians. Only few studies have focused on overall survival. A recent population-based study comparing white and AA subjects showed a better survival in AA patients over a entire study period ranging from 1973 to 2005. However, significant survival improvement after the current era of intensive treatment or new therapies was only seen among whites, with smaller, non-significant change seen among blacks .This study hypothesized that the disparities in improvement in outcome observed could be related to a lower response to new therapies in AA patients. In Martinique, a French overseas department, the vast majority of the population is of Afro-Caribbean origin .
Aims
Our aim was to assess the characteristics, progression-free (PFS) and overall survival (OS) of this ethnicity subgroup.
Methods
We conducted a retrospective study on transplant-ineligible patient, newly diagnosed with MM who were treated in the Hematology Department of Fort de France in Martinique between 2007 and 2012.
Results
During this period, the Martinique Association for Epidemiological Research on Cancer revealed an incidence of 8/100,000 inhabitants per year. Fifty four patients were not eligible for autologous stem cell transplantation and had been treated with melphalan, prednisone and thalidomide as part of frontline therapy.The patients had a median age of 80 years, with ISS stage III documented in 48%. The overall response rate was 76%. With a median follow up of 35 months, PFS and OS were 28.9 months and 48.6 months.
Summary
Compared to metropolitan France, our results show a higher incidence and a similar outcome in this population, despite an advanced age and disease status at diagnosis. No data have been published focusing only on the outcome of AA or African-Caribbean elderly patients treated with combination therapies that include novel agents. Our study highlights findings which had so far not been described and do not support the hypothesis that AA patients had a lower response to new therapies.
Keyword(s): Elderly, Ethnicity, Multiple myeloma
Session topic: Publication Only
{{ help_message }}
{{filter}}